Pioneer in the development of novel therapeutics targeting cancer stem cells-- OncoMed Pharmaceuticals -- has been issued U.S. Patent No. 7,115,360 entitled "Isolation and Use of Solid Tumor Stem Cells” by the USPTO.
According to John Lewicki, Ph.D., Senior Vice President Research and Development:
"Our latest patent provides us with important intellectual property as we develop new means for designing and testing therapies that target cancer stem cells.
We believe that our approach using isolated and purified cancer stem cells will be a better predictor of the efficacy of new cancer therapeutics compared with current conventional approaches in cancer research."
The said patent covers OncoMed's proprietary approach for testing of cancer stem cell therapeutics to inhibit human tumor growth in preclinical models, enabling OncoMed to identify potential cancer therapeutics that inhibit tumor growth following injection of cancer stem cells obtained from a patient's tumor.
Find more details from the press release.
Comment Preview